[ad_1]
KUALA LUMPUR: Bintai Kinden Corporation Bhd’s partner, Generex Biotechnology Corporation, has signed a Framework Agreement for the development and commercialization of the II-Key-SARS-CoV-2 coronavirus vaccine in China.
The agreement was signed with the Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd.
In a statement today, Bintai Kinden said that under the agreement, Generex would receive upfront development fees and back-end license payments.
Meanwhile, the partners would conduct research and development, and pay 100 percent of the funds required for commercial approval of the Ii-Key-CoV-2 vaccine, including laboratory work, manufacturing, regulatory records, and the program. clinical development for regulatory approval. of the vaccine in China.
He said that the Ii-Key-SARS-CoV-2 vaccine was designed as a “complete vaccine” that has the potential to induce T-cell and antibody immune responses in a highly specific way that could provide protective immunity with long-lasting immunologicals. . memory against SARS-CoV-2 and other pandemic threats such as Covid-19 and swine flu.
Managing Director Ong Choon Lui said that the partnership between Generex, China CDC, Beijing Guoxin Haixiang and Beijing Youfeng reaffirmed the potential of Ii-Key technology in developing safe and effective vaccines for infectious diseases and cancer.
“Involvement of China’s state-owned fund and cooperation at the highest level of government through the China CDC increase the likelihood of successful vaccine marketing efforts,” he said.
Bintai Kinden said that its subsidiary, Bintai Healthcare Sdn Bhd, had signed an agreement with Generex and its subsidiary, NuGenerex Immuco-Oncology Inc in October for the distribution and license of its Covid-19 vaccine in Malaysia.
He said the agreement gave Bintai Healthcare exclusive rights to distribute, sell and market the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.
“He will also have the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market,” he added.
China CDC is a government and national technical organization specialized in disease control and prevention and public health, and Beijing Guoxin Haixiang is a limited company established to fund the association’s research and development efforts.
Meanwhile, Beijing Youfeng is the Public Health Working Committee of China High-Tech Industrialization Research Society that provides consulting and design of project development, implementation and management strategies. -Called
[ad_2]
